The AI powered next-generation delivery system for genes

Our non-lipid polymer-based nanoparticles are safer and more effective than other delivery systems — and our team is the expert partner you’ll wish you always had.   

Get started with a proof-of-concept kit.

Get started

Made from
FDA-approved materials

Non-toxic and
non-immunogenic

Suitable for multiple dosing

Superior transfection and yield

THE ENVOYA EDGE

Take your work to the next level

With our Envoyer nanoparticles as your delivery system, you’ll be able to run more successful experiments than ever.

Deliver payloads more effectively

Our nanoparticles can deliver larger payloads than other delivery systems, so you won’t have to minimize the base pair size. They achieve superior encapsulation efficiency, losing significantly less genetic material than LNPs, and superior transfection efficiency of 80-90%.

Create safer treatments

Made from FDA-approved materials, our nanoparticles are non-toxic in murine models, do not elicit an immune response, and do not accumulate in the liver. With a better safety profile than other delivery systems, they are suitable for multiple dosing.

Partner on customization

Partnering closely with you and your team, we’ll tailor our nanoparticles to your specific use case and make changes to suit your needs. We’re committed to doing everything we can to put you in a position to succeed.

Leave the prep work to us

To save you time and effort, we do the formulation, optimization, and encapsulation for you. Just tell us the payload and we handle the rest.

Envoya vs. other delivery systems

PARAMETER

ENVOYERS

LIPID NANOPARTICLES (LNPS)

VIRAL VECTORS

Transfection Efficiency

45-55% for mRNA ,  ~80% for pDNA

40-60% for mRNA , 20-30% for pDNA

Up to 80% depending on vector

Immunogenicity

Minimal cytokine activation

20-40% show cytokine elevation

30-50% develop neutralizing antibodies

In Vivo Knockdown Efficiency

50-70% gene knockdown at 0.2 mg/kg

50-70% gene knockdown at 2.5–5 mg/kg

60-80% gene knockdown, dose-dependent

Toxicity and Liver Function

No significant liver toxicity

10-20% incidence of liver enzyme elevation

Long-term safety concerns due to genomic integration

Stability

Short term stability at RT, 4°C, -20°C. Long term
(6 months) stability at -80°C, lyophilized

Requires -80°C for long-term storage

Requires refrigeration or freezing, depending on vector

Payload Capacity

Suitable for larger genetic payloads like pDNA

Limited by size and charge of payload

Limited (~4.7 kb, varies by vector)

Ease of Manufacturing

Easier to scale and produce

Complex, especially for sterile formulations

Highly complex and costly

Safety Concerns

Reduced due to low immunogenicity and toxicity

Concerns from immunogenicity and potential toxicity

Integration into host genome poses risks.

References‍

Hajj, K. A., & Whitehead, K. A. (2017). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2(10), 1-17.
Hassett, K. J., et al. (2019). Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ter., 27(12), 1901-1910.
Kulkarni, J. A., et al. (2018). Lipid Nanoparticles Enabling Gen. Ter.: From Concepts to Clinical Utility. Nucleic Acid Therapeutics, 28(3), 146-157.
Shir.orr.day3.S1.pptx (Internal document from Envoya, provided by the user).
Suzuki, Y., et al. (2018). Engineered Lipid Nanoparticles for siRNA Delivery: Lessons from Recent Advances in Nanomedicine. Journal of Controlled Release, 286, 221-238.
Sago, C. D., et al. (2020). High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proceedings of the National Academy of Sciences, 115(20), E9944-E9952.

FROM OUR FOUNDER

Gene delivery should be saving or improving millions more lives each year.

But conventional delivery systems aren’t good enough.

They cause immune reactions. They accumulate in the liver. They can’t encapsulate large payloads. And every year, thousands of promising innovations are rejected.
‍
As someone whose family suffers from genetic muscular dystrophy disease, I am intimately aware of the consequences of limited delivery systems. That’s why I created Envoya.
‍
I’ve been working with natural polymers since I was 18 years old. I did my PhD in biotechnology engineering and immunology, then completed my academic career with a postdoc at Harvard Medical School. Now, we’re using non-lipid polymer-based nanoparticles to unlock new possibilities.
‍
Our mission is to change the future of healthcare. We’d love to work with you to make it happen.

Shira Orr, PhD.

Founder & CEO

Backed by results

No immune response elicited

Envoyers, LNP: 0.1 mg/kg siRNA 

LPS: ~ 5mg/kg

Tumor growth safely inhibited in murine models

Intra-Tumor Dosing: ~0.2mg/kg 3 times per week (QoD) 

*Model is subQ PANC1 cell line

Superior transfection and encapsulation efficacy

1. pDNA: Envoyers are superior to LNPs in encapsulation and transfection 

2. pDNA: Envoyers are superior to lipofectamine in transfection

Get proof of concept fast

Discover our delivery system with ready-made GFP Envoyers. Easy to use, no NDA required, ships within 24 hours.